Kobe0065 exhibits potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM. Kobe0065 reduced the amount of c-Raf-1 associated with H-Ras G12V in NIH 3T3 cells in a dose-dependent manner, indicating the inhibition of the cellular activity of Ras. Kobe0065 at 20 μM efficiently inhibited the phosphorylation of MEK and ERK, downstream kinases of Raf in NIH 3T3 cells transiently expressing H-Ras G12V, although the effect was slightly weaker than that of 2 μM sorafenib.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction.
Shima F, et al. Proc Natl Acad Sci U S A. 2013 May 14;110(20):8182-7. PMID: 23630290.
|Related Ras Products|
ARS-1630 is a novel mutant K-ras G12C inhibitor.
ARS-1323 is a novel inhibitor of mutant K-ras G12C.
ARS-1620 is an atropisomeric selective KRAS-G12C inhibitor with desirable pharmacokinetics.
ML-098 is an activator of the GTP-binding protein Rab7 with EC50 value of 77.6 nM.
CCG-1423 is a novel specific inhibitor of RhoA transcriptional signaling.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.